Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...

Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

Despite CVS Health's issues, its prospects and solid dividend program make it attractive for income seekers. Johnson & ...

NEW YORK — Johnson & Johnson said on Wednesday it temporarily ... The Manufacturer and User Facility Device Experience, a database of medical device reports submitted to the FDA by manufacturers ...

"Johnson & Johnson MedTech’s Dual Energy Catheter gains CE mark approval" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

Johnson & Johnson (NYSE:JNJ) is a diversified healthcare and general wellness firm with a presence in the pharma, medical devices, and other markets. Its shares are down by 12% over the past year ...